<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>simulations_8k-ex9901.txt
<TEXT>
<PAGE>
EXHIBIT 99.1


SIMULATIONS PLUS
Integrating Science and Software

For Further Information:
SIMULATIONS PLUS, INC.
42505 10th Street West
Lancaster, CA 93534-7059

CONTACT:
Investor Relations
------------------
Ms. Renee Bouche
Simulations Plus, Inc.
661.723.7723
info@simulations-plus.com

For Immediate Release:

October 23, 2008

               SIMULATIONS PLUS ANNOUNCES SHARE REPURCHASE PROGRAM

       UP TO $2.5 MILLION OVER 12 MONTHS AUTHORIZED BY BOARD OF DIRECTORS

LANCASTER, CA, OCTOBER 23, 2008 - Simulations Plus, Inc. (Nasdaq: SLP), the
leading provider of simulation and modeling software for pharmaceutical
discovery and development, announced today that its board of directors has
authorized a share repurchase program effective Monday, October 27, 2008.

Ms. Momoko Beran, chief financial officer of Simulations Plus, said: "The board
of directors has authorized a share repurchase program enabling the buyback of
up to $2.5 million in shares during a 12-month period beginning Monday, October
27, 2008. Repurchases may be made in the open market, through a broker, or
through privately negotiated transactions, subject to market conditions,
applicable legal requirements and other factors. Simulations Plus has no
obligation to repurchase shares under the repurchase program and the timing,
actual number, and price of shares to be purchased will depend on the
performance of Simulations Plus' stock price, general market conditions, and
various other factors. Such purchases, if any, will be made in accordance with
applicable insider trading and other securities laws and regulations within the
discretion of management."

Walt Woltosz, chairman and chief executive officer of Simulations Plus, added:
"At this time, the board believes that the undervaluation of our stock has
become so severe, and our accumulation of cash has continued so well, that using
some of it for this purpose is warranted, subject to management's discretion and
market conditions as Ms. Beran has described. Authorizing this amount is not
expected to interfere with potential acquisitions or with meeting operating
requirements, which the board believes are of utmost priority."

ABOUT SIMULATIONS PLUS, INC.

Simulations Plus, Inc. is a premier developer of groundbreaking drug discovery
and development simulation software, which is licensed to and used in the
conduct of drug research by major pharmaceutical and biotechnology companies
worldwide. We have two other businesses that are based on our proprietary
technologies: a wholly owned subsidiary, Words+, Inc., which provides assistive
technologies to persons with disabilities; and an educational software series
for science students in middle and high schools known as FutureLab(TM). For more
information, visit our Web site at www.simulations-plus.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
- With the exception of historical information, the matters discussed in this
press release are forward-looking statements that involve a number of risks and
uncertainties. The actual future results of the Company could differ
significantly from those statements. Factors that could cause or contribute to
such differences include, but are not limited to: the ability of the Company to
maintain its competitive advantage, the general economics of the pharmaceutical
industry, the ability of the Company to finance growth, and a sustainable
market. Further information on the Company's risk factors is contained in the
Company's quarterly and annual reports as filed with the Securities and Exchange
Commission.

                                       ###




</TEXT>
</DOCUMENT>
